ReviewNPJ vaccines2023
Is new dengue vaccine efficacy data a relief or cause for concern?
Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- Adjacent spillover efficacy of Wolbachia for control of dengue: emulation of a cluster randomised target trial.BMC medicine · 2025Trial
- Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.The Lancet. Infectious diseases · 2024Trial
- Vaccinology in the twenty-first century revisited.NPJ vaccines · 2026Article
- Evaluating knowledge and attitudes towards dengue fever and its vaccination in China: A questionnaire-based study in healthcare practitioners.PLoS neglected tropical diseases · 2026Article
- Identification of multiple arbovirus infections/exposure in Northeastern Brazil using a multiplex microsphere immunoassay.Journal of clinical microbiology · 2026Article
- Heterogeneity and dynamics of DENV-specific CD8 + T cells in dengue infection.Nature communications · 2026Article
- Plasma proteomics identifies early markers of endothelial and inflammatory activation associated with dengue disease severity in children.medRxiv : the preprint server for health sciences · 2026Article
- Dengue infection elicits skin tissue-resident and circulating CD8Science advances · 2026Article
- Efficacy of phytochemicals derived from Artocarpus heterophyllus (Jackfruit) as inhibitors against NS2B/NS3 protease of dengue virus: an in-silico investigation.Scientific reports · 2026Article
- The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine.NPJ vaccines · 2026Review
- Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations.International journal of molecular sciences · 2026Review
- Comparative analysis of placental transmission mechanisms for Dengue and Zika viruses: outcomes and future directions.Frontiers in immunology · 2026Review
- Proceedings of the inaugural symposium on dengue human challenge studies "Challenging the norm: Accelerating dengue countermeasures through human studies".PLoS neglected tropical diseases · 2026Article
- The Links Between Dengue Virus, Climate and Climate Change.Current topics in microbiology and immunology · 2026Review
- Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates.Nature communications · 2025Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination.Human vaccines & immunotherapeutics · 2025Review
- Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein.Journal of travel medicine · 2025Article
- Antiviral Compounds from Natural Sources Against Human Arboviruses: An Updated Review Including Illustrative In Silico Analysis.Pathogens (Basel, Switzerland) · 2025Review
- Structural dynamics of dengue virus UTRs and their cyclization.Biophysical journal · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a major global public health problem requiring a safe and efficacious vaccine as the foundation of a comprehensive countermeasure strategy. Despite decades of attempts, the world has a single dengue vaccine licensed in numerous countries, but restrictions and conditions of its use have deterred uptake. Recently, clinical efficacy data has been revealed for two additional dengue vaccine candidates and the data appears encouraging. In this perspective I discuss dengue, the complexities of dengue vaccine development, early development setbacks, and how the latest data from the field may be cause for measured optimism. Finally, I provide some perspectives on evaluating dengue vaccine performance and how the pursuit of the perfect dengue vaccine may prevent advancement of vaccines which are good enough.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.